Search Results
Your search for The ASCO Post matches 17812 pages
Showing 12501 - 12550Why Curing Cancer Will Take Decades
This past summer, Eric S. Lander, PhD, President of the Broad Institute of the Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, and Co-Chair of the President’s Council of Advisors on Science and Technology, raised a few eyebrows at the Aspen Ideas Festival when he...
FDA Grants Breakthrough Therapy Designation for First-Line Treatment of ALK-Positive NSCLC
On October 4, 2016, the U.S. Food and Drug Administration (FDA) granted alectinib (Alecesna), an anaplastic lymphoma kinase (ALK) inhibitor, a second Breakthrough Therapy designation. This latest designation was granted for the treatment of adult patients with advanced ALK-positive non–small...
Bridging the Gap in Oncology Care
The third annual Palliative Care in Oncology Symposium, held on September 9–10, 2016, in San Francisco, California, brought together more than 650 attendees from multiple countries, including the United States, Canada, the United Kingdom, France, Italy, and China. It featured over 250 study...
COA Releases 2016 Community Oncology Practice Impact Report
The Community Oncology Alliance (COA) released the 2016 Community Oncology Practice Impact Report today, which tracks the changing landscape of cancer care in the United States. It documents a 121% increase in community cancer clinic closings and a 172% increase in consolidation into hospitals...
ASCO Presents First-Ever Congressional Leadership Award to Rep. Michael Burgess, MD
ASCO presented Representative Michael Burgess, MD (TX-26) with its first-ever ASCO Congressional Leadership Award on September 21 to recognize his steadfast work to support policies related to cancer research and treatment. This new, annual award honors a member of Congress who is a consistent...
AMA Awards Research Grants to Advance the Study of Women in Medicine
Each September, the American Medical Association (AMA) recognizes influential women physician leaders as part of Women in Medicine Month. To showcase the accomplishments of these leaders, the AMA Women Physicians Section and the AMA Foundation (AMAF) have announced the winners of the 2016 Joan F....
Metastatic Breast Cancer Alliance Launches ‘Help Keep Me in the Picture’ Campaign
To raise awareness and support for those with metastatic breast cancer, the Metastatic Breast Cancer Alliance launched its “Help Keep Me in the Picture” campaign. The campaign includes a social media initiative and a new microsite—KeepMeInThePicture.com—which shares stories from patients,...
Salk Institute’s Clodagh O’Shea, PhD, Named Howard Hughes Medical Institute Faculty Scholar
Clodagh O’Shea, PhD, Associate Professor in the Salk Institute’s Molecular and Cell Biology Laboratory, is among the first recipients of a grant from the Faculty Scholars Program, a new partnership of Howard Hughes Medical Institute (HHMI), the Bill and Melinda Gates Foundation, and the Simons...
Baylor and Texas Children’s Hospital Partner to Bring Fellowship Training in Oncology and Hematology to East Africa
Medical students and practicing pediatricians in Uganda and other East African countries lack access to specialty pediatric training and education in oncology and hematology in their region, despite the need for doctors to provide care for patients with cancer and blood disorders. A new program of...
Surgery and Radiation ProtecT Against Progression/Metastasis vs Active Monitoring in Prostate Cancer, but at What Cost?
The ProtecT trial showing similar 10-year survival with active monitoring, surgery, or radiotherapy for prostate-specific antigen (PSA)-detected localized prostate cancer but a greater risk of disease progression/metastasis with monitoring was recently reported by Hamdy and colleagues and is...
FDA Approves Osimertinib Blood-Based T790M Companion Diagnostic Test
On September 29, the U.S. Food and Drug Administration (FDA) approved a blood-based companion diagnostic for osimertinib (Tagrisso). The companion diagnostic for osimertinib is the only FDA-approved and clinically validated companion diagnostic test that uses either tissue or a blood sample ...
NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms
Myeloproliferative neoplasms are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. These cancers—myelofibrosis, essential thrombocythemia, and polycythemia vera—affect approximately 13,000, 134,000, and 148,000 patients ...
ASTRO 2016: Extremely Hypofractionated Radiation Therapy Shows Promising Toxicity Results for Intermediate-Risk Prostate Cancer
For men with intermediate-risk prostate cancer, side effects at 2 years following radiation therapy were comparable for extremely hypofractionated treatment, which was delivered in 7 fractions across 2.5 weeks, and conventional treatment of 39 fractions across 8 weeks, according to research...
ASTRO 2016: Intervention Closes Racial Gap and Improves Treatment Rates for Early-Stage Lung Cancer
Enhanced, culturally competent communication with early-stage lung cancer patients can narrow racial gaps in curative treatment completion and increase treatment rates for all races, according to research presented by Manning et al at the 58th Annual Meeting of the American Society for Radiation...
ASTRO 2016: Stereotactic Radiosurgery Decreases Rate of Postoperative Local Recurrence for Brain Metastases
Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence, but shows no positive difference in terms of overall survival or distant brain metastases rates when compared to observation alone following surgical...
ASTRO 2016: SBRT Offers Patients With Prostate Cancer High Disease Control and Low Toxicity in Fewer Treatments
High-dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates, according to research presented by Meier et al at the 58th Annual Meeting of the...
ASTRO 2016: Hypofractionated Radiation Therapy May Halve Treatment Time for Lung Cancer Patients With Poor Performance Status
For patients with stage II and III non–small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation, hypofractionated radiation therapy results in similar overall survival and progression-free survival rates, limited severe side effects, and shorter...
ASTRO 2016: Reduced Radiation Boost Volume Recommended for Average-Risk Pediatric Medulloblastoma, but Craniospinal Axis Dose Remains Unchanged
In the largest trial conducted for average-risk medulloblastoma, survival rates following reduced radiation therapy boost volumes were comparable to standard treatment volumes for the primary tumor site, but lower doses of craniospinal axis irradiation were associated with higher event rates and...
ASTRO 2016: Postoperative Stereotactic Radiosurgery: New Standard of Care for Patients With Resected Brain Metastases?
For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline, and better quality of life, compared to whole-brain radiotherapy (WBRT), according to research presented at the 58th Annual ...
Meena Moran, MD, on Ductal Carcinoma In Situ: Improving Local Control
Meena Moran, MD, of Yale University, discusses an analysis from 10 pooled academic institutions that showed a radiation boost after whole breast radiation therapy improves local control of this disease. (Abstract 324)
Paul L. Nguyen, MD, on Prostate Cancer: High-Risk Disease, Brachytherapy, And Hormones
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability after the procedure, and androgen deprivation and high-dose radiotherapy. (Scientific Session 41)
Maria Werner-Wasik, MD, on Issues in Lung Toxicity
Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation to thoracic vertebral bodies, radiation pneumonitis, and upfront SBRT. (Scientific Session 39)
ASTRO 2016: Three Novel Intrinsic Subtypes of Prostate Cancer Identified
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research...
ASTRO 2016: Advances in Radiation Therapy Have Improved Survival Rates for Patients With Early-Stage Lung Cancer
A new analysis of records in the Veterans Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non–small cell lung cancer (NSCLC) in recent years, according to research presented...
ASTRO 2016: Radiation Boost Reduces Local Tumor Recurrence for Patients With DCIS Following WBRT
A supplemental “boost” of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with ductal carcinoma in situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research ...
ASTRO 2016: Intermediate-Risk Prostate Cancer May Be Well Controlled With Brachytherapy Alone
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research...
ASTRO 2016: Unmet Need for Radiation Therapy Found Among Nearly Half of Eligible Cancer Patients in Nine Developing Countries
Although approximately 50% of cancer patients in developing countries need radiation therapy to treat their disease, up to half of these patients do not have access to it, according to research presented by Rosenblatt et al at the 58th Annual Meeting of the American Society for Radiation Oncology...
ASTRO 2016: Hypofractionated Radiation Therapy Can Reduce Treatment Time With Comparable Quality of Life for Patients With Prostate Cancer
For men with early stage, low-risk prostate cancer, treatment with hypofractionated radiation therapy offers comparable health-related quality of life outcomes in one-third less treatment time than conventional radiation therapy, according to research presented by Watkins Bruner et al at the 58th...
ASTRO 2016: Widespread Adoption of SBRT Has Improved Survival Rates for Elderly Patients With Early-Stage Lung Cancer
Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non–small cell lung cancer (NSCLC) rose from roughly 40% to 60% over the past decade, concurrent with the increasing adoption of SBRT, according to research presented by Dalwadi et al...
ASTRO 2016: Cervical and Endometrial Cancer Patients Report Fewer Side Effects and Better Quality of Life With IMRT
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy, according to research presented by Klopp et al at...
Thomas J. Lynch, Jr, MD, on Personalized Care and Radiation Oncology in Lung Cancer
Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)
Richard T. Hoppe, MD, on Lymphoma: Improving Outcomes
Richard T. Hoppe, MD, of Stanford University, summarizes a session on improving outcomes by enhancing old and new indications in follicular lymphoma and Hodgkin lymphoma. (Scientific Session 5)
Bradley R. Prestidge, MD, on Prostate Cancer: Initial Findings of NRG Oncology/RTOG 0232
Bradley R. Prestidge, MD, of Bon Secours VA Health System, summarizes his plenary lecture on this phase III trial comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostate cancer....
Alan Pollack, MD, PhD, on Prostate Cancer: Postprostatectomy Radiotherapy
Alan Pollack, MD, PhD, of the University of Miami Health System, summarizes a session that included discussion of outcomes, dose response, oligometastatic disease, and gene predictor of response. (Presentations 228-235)
Joanne B. Weidhaas, MD, PhD, on Head and Neck Cancer: Results of the NRG Oncology/RTOG 0522 Study
Joanne B. Weidhaas, MD, PhD, of the University of California, Los Angeles Radiation Oncology, discusses the KRAS variant as a biomarker of cetuximab response and altered immunity in head and neck cancer. (Abstract LBA-11)
Anders Widmark, MD, PhD, on Intermediate-Risk Prostate Cancer: Results From the HYPO-RT-PC Trial
Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)
Takeshi Kodaira, MD, PhD, on Glottic Cancer: Results of a Japan Clinical Oncology Group Study
Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)
Louis Harrison, MD, on Radiation Oncology and the Future of Health Care
Louis B. Harrison, MD, of the Moffitt Cancer Center, discusses radiation oncology in the context of personalized medicine, multidisciplinary care, new technology and applications, and the mandate to contain costs.
Lia M. Halasz, MD, on Disparities in Radiotherapy Delivery 126
Lia M. Halasz, MD, of the University of Washington Seattle Cancer Care Alliance, summarizes a session on the uneven delivery of radiotherapy in the United States and around the world. (Scientific Session 10)
Howard M. Sandler, MD, on RTOG’s Past and NRG’s Future 126
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)
Daniel Hamstra, MD, PhD, on Prostate Cancer: Decreasing Rectal Toxicity 126
Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)
Brian Kavanagh, MD, MPH: Looking Ahead With ASTRO’s President-Elect
Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.
Bruce D. Minsky, MD's, Meeting Highlights: An Expert Perspective
Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.
Douglas W. Arthur, MD, on Breast-Preserving Surgery: Results From NRG Oncology/RTOG 1014 126
Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from a phase II study of repeat breast-preserving surgery and 3D conformal partial breast reirradiation for in-breast recurrence. (Abstract LBA-10)
Addition of CHK1 Inhibitor Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
Combining a new targeted drug that blocks one of cancer’s escape routes could boost the effectiveness of combined chemoradiotherapy for head and neck cancers and stop cells becoming resistant to treatment. Researchers at The Institute of Cancer Research, London (ICR), and The Royal Marsden...
Blood Biomarkers in Abiraterone- or Enzalutamide-Resistant Prostate Cancer Tumor Cells
While searching for a noninvasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies. In a study published by Gupta et al in Clinical Cancer Research, a team...
Large Study Finds No Link Between Vasectomy and Prostate Cancer Risk
In a new study, men who underwent vasectomy did not have an increased risk of prostate cancer, nor were they more likely to die from prostate cancer than men who did not receive this procedure. According to the researchers, this is the largest prospective study of vasectomy and fatal prostate...
Saul J. Sharkis, PhD, Stem Cell Researcher, Dies
Saul J. Sharkis, PhD, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died on September 4. He was 72. Dr. Sharkis was Professor of Oncology at the Johns Hopkins University School of Medicine and a faculty...
Study Confirms Benefit of Cobimetinib Plus Vemurafenib in Advanced BRAF V600–Mutant Melanoma
As reported by Ascierto et al in The Lancet Oncology, longer-term follow-up in the pivotal phase III coBRIM trial confirmed the benefit of adding cobimetinib to vemurafenib (Zelboraf) in first-line treatment of BRAF V600–mutant unresectable stage IIIC or IV melanoma. Grant A. McArthur, FRACP, of...
Combining Ipilimumab With Radiotherapy in Advanced Melanoma
The immunotherapy ipilimumab (Yervoy) has revolutionized the treatment of malignant melanoma and resulted in durable responses in 20% to 25% of patients with the cancer. Sebastian Theurich, MD, of the Center for Integrated Oncology at the University Hospital of Cologne in Germany, and colleagues...
